

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14620-0012US1	Application No. 09/622,433
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Bastian Nuyen et al.	
		Filing Date May 10, 2002	Group Art Unit 1655

### U.S. Patent Documents

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	1						
	2						
	3						
	4						
	5						
	6						
	7						
	8						
	9						
	10						
	11						

### Foreign Patent Documents or Published Foreign Patent Applications

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	12	WO 98/50048	11/12/1998	WIPO				
	13	WO 99/42125	08/26/1999	WIPO				
	14	1 054 686	05/15/2002	Europe				
	15							
	16							

### Other Documents (include Author, Title, Date, and Place of Publication)

Examiner Initial	Desig. ID	Document
	17	NUIJEN ET AL., "Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Novel Antitumor Agent Aplidine", PDA Journal of Pharmaceutical Science & Technology, vol. 54, no. 3, May/June 2000, pp. 193-208
	18	"Mannitol", Handbook of Pharmaceutical Excipients, Second Edition, Edited by Ainley Wade and Paul J. Weller, 1994, pp. 294-298
	19	
	20	

Examiner Signature	Date Considered
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	